Lv11
60 积分 2025-04-02 加入
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
2天前
已完结
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
5天前
已完结
Mucinous Ovarian Carcinoma
7天前
已完结
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
1个月前
已完结
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
1个月前
已完结
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
1个月前
已完结
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
1个月前
已完结
Mucinous Ovarian Carcinoma
2个月前
已完结
Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability
2个月前
已完结
Neoadjuvant Immune Checkpoint Inhibitor Therapy for Localized Deficient Mismatch Repair Colorectal Cancer
2个月前
已完结
皖公网安备34019202002308
